How go/no-go assessment supports strategic decision-making

Last updated: 3rd April, 2026

Decision‑making across complex pipelines requires balancing clinical opportunity with access potential, pricing expectations, and evolving health technology assessment requirements. Early clarity is essential to prioritise assets, align investment, and reduce downstream risk.

A structured go/no‑go assessment provides leaders with a consistent framework for evaluating feasibility and strategic fit across the portfolio. By examining clinical, access, pricing, and evidence considerations together, teams can make more confident decisions under uncertainty and focus resources where they matter most.

Technical expertise supporting assessment strategy

Our specialists combine strategic insight and clinical knowledge to build models that drive meaningful decisions.

Reviewing development profiles
Each asset’s development profile is reviewed to assess assumptions that underpin strategic positioning and feasibility.

Assessing the market access environment
Key market access factors are reviewed, including the access landscape and relevant system considerations that may influence future decisions.

Considering HTA requirements
HTA considerations are incorporated to reflect how evidence and value may be assessed during future evaluations.

Practical agility supporting decision delivery

We deliver solutions efficiently by combining a lean structure with rapid collaboration, keeping projects responsive to evolving needs.

1. Establishing access and pricing implications: Market access and pricing implications are established across relevant domains to support strategic evaluation.
2. Identifying value drivers: Key value drivers are identified from assessment parameters to inform ‘go’ or ‘no go’ considerations across the portfolio.
3. Quantifying market value: Pricing calculations are developed using value-based approaches to support understanding of potential market value.
4. Summarizing go- or no-go direction: A structured summary indicates the relative favorability of each asset across key domains, supporting informed decision-making.
5. Identifying evidence needs: Evidence requirements are identified, and activities are recommended to address data gaps and support future decisions.

Our expert support

Applying a structured go/no‑go assessment helps teams prioritise assets, allocate resources with intent, and reduce uncertainty in pipeline decision‑making. By connecting clinical insight, access realities, pricing considerations, and evidence planning, Acumetis works alongside leaders to reframe what’s possible in portfolio strategy and development decision‑making.

Our expert support brings perspective, challenge, and continuity, helping teams move forward with confidence as strategic priorities take shape. Connect with our experts to support informed, decision‑ready planning across your pipeline.